Trumpcare Needs Milton Friedman

Trumpcare has focused exclusively on eliminating mandates, reducing tax credits, and rolling back Medicaid expansion to the working poor. But, the consequences of this are an estimated 24 Million people dropping coverage and huge increases in premiums for those who wish to remain covered. Trumpcare is up for a vote in the House of Representatives and […]

Pharmacy Benefit Managers

CURRENT PAPERS ON PBMs A Position Auction Demonstration Project for Lowering Reference + Biosimilar Rx Drug Prices in Medicare Part B  (8/19) Off-Target: Pelosi’s Binding Arbitration Proposal to Reduce Medicare Part D Drug Prices (04/19) Quantifying a Pharmacy Benefit Manager (PBM) Fee-For-Service Business Model   (03/19) CVS’s Negligent Handling of Its 2019 Formulary Change In Coverage […]

Pharmacy Benefit Manager Rx Drug Rebates – PBMs

A Position Auction Demonstration Project to Lower Reference + Biosimilar Rx Drug Prices in Medicare Part B (8/19)  Pharmacy Benefit Managers as Conflicted Countervailing Powers (01/07) Who is Best at Negotiating Pharmaceutical Rebates? (12/05) The Role of Pharmacy Benefit Managers in Formulary Design: Service Providers or Fiduciaries? Journal of Managed Care Pharmacy Vol. 10 No. […]

The Pharmacy Benefit Manager (PBM) Business Model

CURRENT PAPERS: Quantifying a Pharmacy Benefit Manager (PBM) Fee-For-Service Business Model (03/19) The Problem with CVS’s “Guarantee Net Cost” PBM Business Model (12/18) Three Phases of the Pharmacy Benefit Manager Business Model (09/17) Will Amazon’s Online Pharmacy Display Therapeutic Equivalents (12/17) Blame PBMs (Not Pharma) For Driving Drug Price Inflation (09/17) Merck Data Discredits PBM-Sponsored Study of […]

Preferred Provider Pharmacy Networks

PREFERRED PROVIDER PHARMACY NETWORKS The CVS-Caremark Merger and the Coming Preferred Provider War (12/06) Medicare Part D and Preferred Provider Pharmacy (04/05) The CVS-Caremark Merger: The Creation of an Elasticity of Demand for Retail Rx (11/06) Contrary to What Wall Street and the FTC Say, The PBM Business Model is Misaligned (11/05) Sins of Omission’: […]

PBM Legal and Antitrust Issues

Off-Target: Pelosi’s Binding Arbitration Proposal to Reduce Medicare Part D Drug Prices (4/19) Insulin Drug Price Inflation: Racketeering or Perverse Competition (1/18) Biosimilars & Exclusive Dealing Antitrust Law: The Case of Pfizer Inc v Johnson & Johnson et al. (10/17) Biosimilar Drugs in 2017: Good for Competition, Bad for the Competitors (12/17) Was CVS’s Formulary […]